## Monitoring Statin Therapy: Investigation of Choice ### Rationale for Serum Lipid Profile and Liver Function Tests **Key Point:** The dual assessment of lipid profile and liver function tests (LFTs) is the gold standard for monitoring statin efficacy and safety in the first 8 weeks of therapy. 1. **Lipid Profile Assessment** - Measures LDL-C, HDL-C, triglycerides, and total cholesterol - Determines whether the statin has achieved target LDL-C (typically <70 mg/dL post-MI) - Guides dose escalation or addition of second-line agents (ezetimibe, PCSK9 inhibitors) 2. **Liver Function Tests** - Baseline LFTs should be done before starting statin - Repeat at 8–12 weeks to detect statin-induced hepatotoxicity - Elevated transaminases (AST/ALT >3× upper limit of normal) warrant dose reduction or discontinuation - Risk increases with higher doses (e.g., atorvastatin 80 mg) and in patients with pre-existing liver disease **High-Yield:** The 2022 ESC/EAS lipid guidelines recommend lipid profile assessment at 4–12 weeks after initiation or dose change, and LFTs at baseline and 8–12 weeks. ### Timing of Investigation | Investigation | Timing | Purpose | | --- | --- | --- | | Lipid profile | 4–12 weeks after initiation | Efficacy assessment; guide intensification | | LFTs | Baseline + 8–12 weeks | Safety monitoring; detect hepatotoxicity | | CK | Only if symptoms (myalgia, dark urine) | Statin-induced myopathy screening | **Clinical Pearl:** In this patient at 8 weeks post-initiation, both investigations are timely and essential. Lipid profile confirms therapeutic benefit in secondary prevention (post-MI), while LFTs ensure no drug-induced liver injury. **Warning:** Do not wait for symptomatic myopathy to check CK—baseline CK is recommended only in high-risk patients (renal impairment, drug interactions, elderly). Routine CK monitoring is NOT recommended unless symptoms emerge.
Sign up free to access AI-powered MCQ practice with detailed explanations and adaptive learning.